AOD-9604 Guide — What It Is, How It Works & What the Research Shows

What it is

AOD-9604 is a synthetic 16-amino-acid peptide based on the tail end (residues 176-191) of human growth hormone (hGH), with an extra tyrosine added at the front. It was designed by Australian company Metabolic Pharmaceuticals in the late 1990s to capture growth hormone's fat-burning region while leaving out the parts that drive tissue growth and raise blood sugar.

Because it is only a small piece of the full hormone, AOD-9604 does not meaningfully bind the growth hormone receptor and does not raise IGF-1, the downstream signal behind most of GH's growth effects. The hope was a targeted 'fat-loss without the side effects' compound.

Despite years of development and six human trials, AOD-9604 was never approved as a drug by the FDA, EMA, or TGA. Today it is sold only as a 'research use only' compound and is not an approved medicine or dietary supplement in the U.S.

How it works

In theory, AOD-9604 mimics the specific part of growth hormone that stimulates lipolysis, the breakdown of stored fat, and increases fat oxidation (burning fat for fuel). In obese mice, it reduced weight gain and boosted fat burning without activating the GH receptor. The appeal was that it could target fat metabolism without GH's downsides, such as elevated blood sugar and joint or growth effects.

The key claimed distinction from full growth hormone is metabolic: human studies found AOD-9604 had no effect on IGF-1 levels and no negative effect on glucose tolerance. So the mechanism is best described as 'the fat-metabolism signal of GH, isolated' — a plausible theory that worked in animals but did not translate into significant weight loss in the pivotal human trials.

What people research it for

Increased fat burning (lipolysis)

Animal studies

In obese mice, AOD-9604 raised fat oxidation and reduced body-weight gain without binding the GH receptor. This is the core rationale for the compound, but it is an animal finding that did not reproduce as meaningful weight loss in large human trials.

No rise in IGF-1 or blood sugar

Early human data

Unlike full growth hormone, human studies found AOD-9604 did not increase IGF-1 and did not worsen glucose tolerance — a favorable metabolic profile, though this is a safety feature rather than a proven benefit.

Modest early weight-loss signal

Early human data

A 12-week Phase 2a study reported slightly more weight loss than placebo, but this was small and was NOT confirmed in the larger, longer pivotal trial. Treat any weight-loss claim with heavy skepticism.

Joint/cartilage and metabolic-health interest

Preclinical / theorized

Some later work and marketing explore AOD-9604 for cartilage or general metabolic health, but these uses are early-stage and theorized, not established in controlled human outcome trials.

What the research actually shows

AOD-9604 completed roughly six human clinical trials involving several hundred participants between about 2001 and 2007. An early 12-week Phase 2a study suggested a modest edge over placebo, which generated optimism and further investment.

The decisive test was a larger, longer Phase 2b trial (536 subjects, 24 weeks, oral doses up to 1 mg/day). It did not meet its primary endpoint: mean weight loss versus placebo was not statistically significant. After this failure, Metabolic Pharmaceuticals halted the obesity drug-development program in 2007.

The honest summary: AOD-9604 is a compound whose central promise — meaningful fat loss in humans — was directly tested in a well-designed trial and did not hold up. Its animal data and safety profile are genuinely interesting, but it is not a proven weight-loss agent. Current sales are for laboratory research, not clinical use.

Research handling & storage

Research AOD-9604 is typically supplied as a lyophilized (freeze-dried) white powder in a sealed vial. In laboratory settings it is reconstituted with bacteriostatic or sterile water, added gently down the vial wall rather than forcefully, then swirled — not shaken — to dissolve, since peptides can be damaged by rough agitation.

Unopened lyophilized vials are generally stored refrigerated and kept away from light and heat; the dry powder is more stable than solution. Once reconstituted, the peptide is far less stable and is kept refrigerated and used within a limited window. These are general handling notes for research material, not instructions for human use.

Safety & cautions

Across its human trials, AOD-9604 was reported as well tolerated, with a safety and tolerability profile described as indistinguishable from placebo, no drug-related serious adverse events, and — notably — no rise in IGF-1 and no adverse effect on blood glucose. Within the trials, its short-term safety looked reassuring.

That said, AOD-9604 is NOT an approved drug or supplement. Trial safety data are short-term and were collected under controlled conditions; there is no long-term human safety data, no regulated manufacturing standard for the 'research use only' product sold online, and purity/contamination cannot be assumed. It is not intended for human consumption in that context.

💰

PRICE ALERTS

Track AOD-9604 prices

Get an alert when a trusted, tested vendor drops the price. Free.

Frequently asked questions

Is AOD-9604 FDA approved?

No. It was investigated as an anti-obesity drug but never approved by the FDA, EMA, or TGA. It is not an approved medication or dietary supplement in the U.S., and it is sold only for laboratory research.

Does AOD-9604 actually cause weight loss?

The evidence says probably not to a meaningful degree. An early small trial hinted at a modest effect, but the larger, longer pivotal Phase 2b trial found no statistically significant weight loss versus placebo, which ended its development in 2007.

How is it different from growth hormone?

It's just a fragment of GH's tail region. Unlike full growth hormone, human studies found it did not raise IGF-1 or worsen blood sugar — but it also did not deliver GH-like results for weight.

Is AOD-9604 the same as HGH Fragment 176-191?

They are closely related. AOD-9604 is based on the hGH 176-191 fragment with an added N-terminal tyrosine; the names are often used interchangeably in the peptide market, though technically AOD-9604 is the specific modified version studied by Metabolic Pharmaceuticals.

Is it safe?

In clinical trials it appeared well tolerated with a placebo-like short-term safety profile, but there is no long-term human safety data, and 'research use only' products are unregulated with no guaranteed purity.

Sources

Last reviewed 2026-07-07. This guide is educational and research-focused — not medical advice. AOD-9604 products referenced on PeptidePub are sold by third parties as materials for laboratory research use only, not for human or animal consumption.

Related peptides

Or compare prices across all peptides.

Ready to compare AOD-9604?

See prices across trusted, third-party-tested vendors, normalized per milligram.

Compare AOD-9604 prices →